3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
4
Thoracic
2
Breast
2
Genitourinary
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
6
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
36
Carboplatin
28
Paclitaxel
23
Filgrastim
17
Nivolumab
14
Gemcitabine
14
Cyclophosphamide
14
Ifosfamide
13
Cisplatin
13
Docetaxel
12
Specimen Handling
11
Etoposide
11
olaparib
9
Peripheral Blood Stem Cell Transplantation
9
Magnetic Resonance Spectroscopy
8
fludarabine
6
Temozolomide
6
Ipilimumab
6
Fluorouracil
6
Biopsy
6
Albumin-Bound Paclitaxel
6
rucaparib
5
avelumab
5
atezolizumab
5
Trastuzumab
5
Thiotepa
5
Taxes
5
Standard of Care
5
palbociclib
4
durvalumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
AZD5305
×
Genitourinary
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled